NCT07717177尚未招募2 期
A Study to Evaluate the Efficacy and Safety of an AI-Driven Treatment Strategy Versus ZR2 in Older Treatment-naive Patients With Large B-cell Lymphoma (LBCL)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 112
- 试验地点
- 1
- 主要终点
- Progression-free survival
研究概览
简要总结
This is a prospective, open-label, multicenter, randomized controlled study in older treatment-naive patients with LBCL. Participants will be stratified into different risk groups using an AI-based multimodal model. Those classified as intermediate- or high-risk will be randomized in a 1:1 ratio to receive either an AI-guided treatment strategy or ZR2. In the experimental arm, participants will receive polatuzumab vedotin in combination with ZR2 or Pola-ZR-Glo regimen (polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab), according to their AI-defined risk group. Participants in the control arm will receive ZR2. The study will evaluate the efficacy and safety of the AI-guided treatment strategy compared with ZR2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must satisfy all of the following criteria to be enrolled in the study:
- •Histologically-confirmed large B-cell lymphoma (without central nervous system involvement)
- •Aged ≥ 70 years old with comprehensive geriatric assessment stratified as unfit or frail, or those who decline immunochemotherapy.
- •After 1 cycle of ZR2, classified as intermediate-risk or high-risk by AI-based multimodal stratification
- •Eastern Cooperative Oncology Group Performance Status 0-2
- •At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)
- •Life expectancy of at least 3 months determined by researchers
- •The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research.
- •Anti-lymphoma drugs have not been used before (except glucocorticoids)
排除标准
- •Presence of any of the following criteria will exclude a patient from enrollment:
- •Uncontrolled blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases
- •Laboratory measures meet the following criteria at screening (unless caused by lymphoma):
- •Neutrophils<1.0×10^9/L Platelets<75×10^9/L ALT or AST is 2.5 times higher than the upper limits of normal (ULN), serum bilirubin are 1.5 times higher than the ULN.
- •eGFR is lower than 30ml/min/1.73m^2 (according to Cockcroft-Gault Equation or MDRD Equation).
- •uncontrollable or significant cardiovascular diseases, including but not limited to: Left ventricular ejection fraction<50% Cardiomyopathy, such as dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy QTc prolongation with clinical significance, QTc interval>470ms (females) or 480ms (males), type 2 second-degree atrioventricular block or third-degree atrioventricular block
- •Patients with HbsAg positive are required to have HBV DNA<1.0×10^3 IU/ml before entering the group. In addition, if the patient is HBsAg negative but HBcAb positive (regardless of HBsAb status), HBV DNA test is also required, and HBV DNA<1.0×10^3 IU/ml is required before entering the group
- •Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol
- •HIV-infected patients
- •History of stroke or intracranial hemorrhage within 6 months prior to start of therapy
- •Other medical conditions determined by the researchers that may affect the study
结局指标
主要结局
Progression-free survival
时间窗: From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 24 months)
PFS, defined as the time from randomization to the first occurrence of disease progression or relapse using the 2014 Lugano Response Criteria or death due to any cause, whichever occurs first.
次要结局
- Event-free survival(Up to approximately 24 months)
- Complete response rate(End of treatment completion , an average of 6 months)
- Objective response rate(End of treatment completion , an average of 6 months)
- Overall survival(Up to approximately 3 years)
- Duration of response(From documentation of CR/PR until relapse/progression or death due to any reason without documented relapse, whichever came first, assessed up to 3 years.)
- Duration of complete response(From documentation of CR until relapse/progression or death due to any reason without documented relapse, whichever came first, assessed up to 3 years.)
- Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v6.0(From enrollment to study completion, a maximum of 4 years)
- Patient reported outcome assessed by EORTC QLQ-C30 (Verison 3.0)(Day 1 of Cycles 1, 4 and 7 (Pola-ZR-Glo regimen only); 30 days after treatment completion. Cycle length=21 days)
- Patient reported outcome assessed by EORTC QLQ-ELD14(Day 1 of Cycles 1, 4 and 7 (Pola-ZR-Glo regimen only); 30 days after treatment completion. Cycle length=21 days)
- Patient reported outcome assessed by FACT-Lym LymS(Day 1 of Cycles 1, 4 and 7 (Pola-ZR-Glo regimen only); 30 days after treatment completion. Cycle length=21 days)
研究者
Zhao Weili
Professor and Director, Shanghai Institute of Hematology
Ruijin Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood TransplantationNCT07441967Institute of Hematology & Blood Diseases Hospital, China44
尚未招募
2 期
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCIntrahepatic CholangiocarcinomaNCT07432568Tianjin Medical University Cancer Institute and Hospital30
尚未招募
不适用
A study to evaluate the efficacy of test regime in lactating females with hair fall.CTRI/2025/07/090485ANVEYA LIVING PRIVATE LIMITED50
已完成
2/3 期
Clinical study on Vimosa Softgel in vaginal dryness and vaginal prolapseCTRI/2024/05/067423Abhinav Health Care Products Pvt Ltd72
尚未招募
不适用
A study to evaluate the efficacy and safety of the test product on the tanned skin.CTRI/2025/09/095413Zydus Wellness Products Limited36